Page 15 - Bharat Biotech

Hester Biosciences zooms 33% in 2 days as firm in talks to produce Covaxin

The company said it has tied up with the Gujarat government to explore the production of Covid-19 vaccine through technology transfer from Bharat Biotech

Covaxin capacity scaled up to 500 million doses a year: Bharat Biotech

Vaccine effective against all emerging coronavirus variants, says study

Hester in talks with Bharat Biotech to produce Covaxin via tech transfer

Hester Biosciences on Sunday said it has tied up with the Gujarat government to explore the production of the Covid-19 vaccine through technology transfer from Bharat Biotech

The vaccine gap

Timelines suggest govt must focus on health infra too

Covaxin effective against India, UK coronavirus strains: Bharat Biotech

Bharat Biotech said its Covid-19 vaccine 'Covaxin' has been found to be effective against coronavirus strains found in India and the UK

Bharat Biotech setting up Covaxin-manufacturing unit in K'taka: Deputy CM

Karnataka will soon have a Covaxin-manufacturing plant of Bharat Biotech in Kolar district near, says Deputy Chief Minister of the State Dr C N Ashwath Narayan

Bharat Biotech dispatches Covaxin to various states like Gujarat, Assam

Bharat Biotech on Friday said it has dispatched COVID vaccine Covaxin to various states like Gujarat, Assam, Tamil Nadu, Karnataka and Odisha. The Hyderabad-based vaccine major, which has come under fire from the Delhi government over supply-related issues, said it has also dispatched Covaxin lots to Kerala and Uttarakhand. "Covaxin goes to Gandhinagar, Guwahati, Chennai, Hyderabad, Bengaluru & Bhuvneshwar. thank all our employees @ BHarat bio who worked thru the holy month of Ramzan..." Bharat Biotech Co-Founder and Joint Managing Director Suchitra Ella said in a tweet. Earlier in a late night tweet on Thursday, she tweeted informing supply of the much in demand vaccine to Kerala and Uttarakhand. "Covaxin sent to Kerala & Uttarakhand. Thanq for the concern, many offered to help. Our work is highly stringent, realtime & technical,no work from home! All Our employees will be taken care of, won't deter us from our mission! Let's be thankful,helpful & hopeful always," she

Bharat Biotech unit to make Pune plant functional for vax production by Aug

Biovet Pvt Ltd, an associate firm of Bharat Biotech, is confident of making a plant at Manjari in Pune fully functional for vaccine production by August-end, a senior administrative official said

India's vaccine supplies to improve as it braces for Covid-19 third wave

India has vaccinated 37.2 million people with both doses of a vaccine, and about 135.5 million have received at least the first jab

Fifty employees of Bharat Biotech test Covid-19 positive: Joint MD Ella

The firm is supplying Covaxin to 18 states, including AP, Haryana, Odisha, Assam, J&K, Tamil Nadu, Bihar, Jharkhand as well as Delhi

Russia's Sputnik V vaccine to be available in India from next week: Govt

India expecting 156 million doses of the vaccine from August to September

Delhi govt urges Serum Institute to 'come to rescue' and provide Covishield

To this, the SII said they are doing their best to meet countrywide vaccine requirements.

Bharat Biotech's Covaxin approved for phase 2/3 trials on children

India's apex drug regulator has granted permission for conducting the phase II/III clinical trial of Bharat Biotech's Covaxin Covid-19 vaccine in the age group of 2 to 18 years

Avoid unrealistic Covid-19 vaccine expectations: Harsh Vardhan to states

The health minister was holding a meeting with eight states that have been showing a higher number of daily cases, positivity rate and mortality

Bharat Biotech trial nod a turning point for paediatric Covid-19 vaccine

Bharat Biotech has already conducted trials on children 12 years and above

Maharashtra, Karnataka suspend Covid-19 vaccination for 18-44 age group

Delhi's Deputy Chief Minister Manish Sisodia accused the Centre of blocking supplies to the state.

Will raise monthly production of vaccines to 100 mn doses by August: Serum

Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September. The Hyderabad-based Bharat Biotech's indigenously developed Covaxin and Oxford-AstraZeneca's Covishield, being manufactured by the Pune-based Serum Institute of India, are currently being used in India's inoculation drive against coronavirus. Dr V Krishna Mohan, the Whole-time Director of Bharat Biotech, is learnt to have conveyed to the government that the production of Covaxin would be raised to 3.32 crore in July, and to 7.82 crore in August which will be maintained in September too. Similarly, Prakash Kum

'Disheartening to see some states complain about our Covaxin intentions'

It is quite disheartening to listen to some states complaining about Bharat Biotech's intentions regarding supply of COVID vaccine Covaxin, a top company official said on Wednesday. In a tweet, Bharat Biotech Joint Managing Director Suchitra Ella said the company has already dispatched Covaxin lots to 18 states on May 10. "18 states have been covered though in smaller shipments. Quite disheartening to the teams to hear some states complaining about our intentions. 50 of our employees are off work due to covid, yet we continue to work under pandemic lockdowns 24x7 for U," she said in a tweet. The Hyderabad-based firm is supplying Covaxin to 18 states, including Andhra Pradesh, Haryana, Odisha, Assam, Jammu & Kashmir, Tamil Nadu, Bihar, Jharkhand and Delhi. Other states are Chhattisgarh, Karnataka, Telangana, Tripura, Madhya Pradesh, Uttar Pradesh, Gujarat, Maharashtra and West Bengal. Earlier in the day, Delhi Deputy Chief Minister Manish Sisodia said Bharat Biotech has informed ...

Experts recommend Covaxin for phase 2/3 trials on those aged 2-18 year

Bharat Biotech's Covid-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said

Direct supply of Covaxin to 18 states since May 1: Bharat Biotech

Bharat Biotech on Tuesday said it will continue the steady supply of its COVID-19 vaccine Covaxin, adding the jab has been directly supplied to 18 states since May 1. The states include Andhra Pradesh, Delhi, Bihar, Gujarat, Haryana, Uttar Pradesh and West Bengal, the Hyderabad-based firm added. "COVAXIN has been directly supplied to 18 states since May 1st. Unflinching in our efforts, we will continue the steady supply of our #vaccine," Bharat Biotech said in a tweet. The company is supplying its vaccine to Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu & Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh and West Bengal. Bharat Biotech has commenced direct supply of Covaxin with effect from May 1 to several states based on the allocations received by the central government, the company's Joint Managing Director Suchitra Ella had earlier said. On April 29, Bharat Biotech had announced a cut